Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis

NCT07611214 is registered in ClinicalTrials.gov with Aurinia Pharmaceuticals Inc. as lead sponsor.

NCT NCT07611214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07611214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis
Lead sponsor
Aurinia Pharmaceuticals Inc.
Phase
Phase 4
Overall status
Recruiting
Start date
April 22, 2026
Completion date
March 2, 2029
Enrollment
150 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis